Geron falls after US FDA staff flags concerns on its blood disorder drug

Geron

12/03/2024 14:51

** Shares of drug developer Geron Corp  GERN.O  fall 4.2% to
$2.05
    ** U.S FDA staff flag efficacy concerns on the late-stage
trial data of co's blood disorder drug in documents that were
released ahead of a meeting of independent experts
    ** The health regulator's staff say it is not clear that the
risks of treatment with the drug, imetelstat, outweigh the
potential benefit for the intended patient population 
     ** The drug was being studied in patients with a type of
blood cancer 
    ** Wedbush analyst Robert Driscoll says that he feels that
Geron will be able to provide a strong case against the points
made by the FDA and expects a positive discussion on Thursday
    ** Including session moves, the stock has fallen 22.6% in
the last 12 months  

 (Reporting by Sneha S K in Bengaluru)
 ((Sneha.SK@thomsonreuters.com;))